What is latest information on ATYR

Here is the latest information on ATYR:

1. **Upcoming Topline Data**: aTyr Pharma is expected to report the topline data from their Phase 3 pulmonary sarcoidosis trial in September 2025. This is a significant milestone for the company as it represents a major inflection point in the development of their lead drug candidate, Efzofitimod.
2. **Financial Position**: The company has reported a quarterly adjusted loss of 22 cents per share for the quarter ended June 30, 2025, with a reported revenue of zero. Despite the loss, the company has a positive cash position, with $83.2 million in cash, cash equivalents, restricted cash, and available-for-sale investments as of June 30, 2025.
3. **Clinical Developments**: aTyr Pharma has made significant progress in its clinical programs, including promising interim data from its Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD, showing improvements in skin fibrosis measures and biomarkers. Additionally, ATYR0101 has advanced to the IND candidate stage for pulmonary fibrosis.

In conclusion, aTyr Pharma is a clinical-stage biotech company with a focus on developing treatments for lung diseases. Their Phase 3 trial for pulmonary sarcoidosis is a key event for the company, and they have a positive financial position to support continued development. Their clinical programs show promise, particularly in systemic sclerosis-related ILD and pulmonary fibrosis.